Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Gives Landmark Nod To Bayer's Vitrakvi

First Histology-Independent Therapy For Patients In England

Executive Summary

Vitrakvi is the first in a new generation of tumor-agnostic drugs to be made available on the NHS after Bayer and NICE finally reached agreement over pricing and access while more data is collected on its clinical effectiveness.

You may also be interested in...



The Tumor-Agnostic Developer’s Toolkit

In Vivo has identified the pipeline of next-generation tumor-agnostic drugs and created a guide to the ideal trial strategies for these potentially transformative candidates.

Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back

Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.

Bayer's Vitrakvi Is EU’s First Tumor-Agnostic Treatment

The German group's cancer drug is the first to be approved for use in Europe for a wide range of tumors. The principal challenge now is to find eligible patients.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL006980

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel